Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842079 | 0.87 | TAAR1 (0.56) | TAAR1HTR2AHTR1DHTR7SMN1; SMN2 | |
| SCHEMBL612360 | 0.84 | TAAR1 (0.47) | TAAR1HTR7MAOACYP2A6CYP1A2 | |
| SCHEMBL8096178 | 0.84 | CYP2A6 (0.45) | TAAR1HTR1DMAPTNPSR1CYP2A6 | |
| SCHEMBL8095408 | 0.84 | CYP2A6 (0.45) | TAAR1HTR1DSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL8093953 | 0.81 | CYP2A6 (0.43) | TAAR1HTR1DSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL8101082 | 0.81 | CYP2A6 (0.43) | TAAR1HTR1DSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL8097070 | 0.81 | CYP2A6 (0.43) | TAAR1HTR1DSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL8093240 | 0.81 | CYP2A6 (0.43) | TAAR1HTR1DSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL8096579 | 0.81 | CYP2A6 (0.43) | TAAR1HTR1DSMN1; SMN2MAPTNPSR1 | |
| SCHEMBL8087584 | 0.81 | CYP2A6 (0.43) | TAAR1HTR1DSMN1; SMN2MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020230132-A1 | COMPOSITIONS FOR CROP PROTECTION | AGREMATCH LTD. (IL) | 2020-11-19 | — | — | WO | disclosed |
| US-20150252056-A1 | BICYCLIC OXA-LACTAM KINASE INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2015-09-10 | — | — | US | disclosed |
| US-5011938-A | Antimicrobials | ELI LILLY AND COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| US-4940718-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| US-4727189-A | ANALGESICS, ANTIHYPERTENSIVE AGENTS | G. D. SEARLE & CO. (US) | 1988-02-23 | — | — | US | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| US-4599325-A | ANALGESIC, HYPOTENSIVE | G. D. SEARLE & CO. (US) | 1986-07-08 | — | — | US | disclosed |
| EP-0154234-A2 | Substituted tyrosil alanine dipeptide amides | G.D. Searle & Co. (US) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252056-A1 | BICYCLIC OXA-LACTAM KINASE INHIBITORS | SYK, BTK, JAK2 | TAAR1 4613/4885HTR2A 4159/4885HTR1D 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.